Biotechnology

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

April 24, 2025 8:00 AM

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function announced positive interim results of an investigator-initiated proof of concept open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in patients with Frontotemporal Dementia (FTD). The study is led by Dr. Alireza Faridar and Dr. Stanley Appel at the...

Read more

Faron Announces Acceptance of Bexmarilimab Phase II Data for Oral Presentation at ASCO 2025

April 24, 2025 2:20 AM

Faron Pharmaceuticals Ltd. (AIM:FARN), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that new Phase II data from its ongoing BEXMAB study evaluating bexmarilimab in high-risk myelodysplastic syndromes (HR-MDS) will be presented as a part of a Rapid Oral Abstract Session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from 30 May to 3 June 2025, in Chicago, Illinois,...

Read more

Alligator Bioscience AB Reports Financial Results for Q1 2025 and Provides a Business Update

April 24, 2025 2:20 AM

Alligator Bioscience (STO:ATORX) 24-month data from OPTIMIZE-1 show 29.4% survival rate for mitazalimab-three times higher than chemotherapy alone FDA alignment secured on Phase 3 strategy following successful End-of-Phase 2 meeting Rights issue completed with gross proceeds of SEK 153 million to support next development stage for mitazalimab Lund, Sweden - Alligator Bioscience (Nasdaq Stockholm: ATORX) "With the continued strengthening of...

Read more

Matter Bio Announces Landmark Collaboration to Decode Exceptional Longevity at Unprecedented Scale

April 23, 2025 3:00 PM

Matter Bio, a pioneering biotechnology company focused on extending healthspan through advanced genetic interventions, today announced the launch of a groundbreaking longevity research initiative that brings together leading scientists and institutions to decode the genetic basis of extreme lifespan. Leveraging multi-omics technologies - including genomics, transcriptomics, proteomics, and metabolomics- and processing this unique dataset with...

Read more

Adolore BioTherapeutics to Present at Festival of Biologics USA 2025

April 23, 2025 1:30 PM

Adolore BioTherapeutics ("Adolore" or the "Company") is developing intracellularly-delivered neuromodulators that naturally reduce neuronal excitability to restore balance to the PNS/CNS to treat the underlying root cause of serious neurological disorders, including chronic pain and announced today Mr. Roelof Rongen, the Company's CEO, is a presenter at the Festival of Biologics USA 2025 meeting, "FOB", on April 24, 2025 in San Diego, Ca....

Read more

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

April 23, 2025 8:00 AM

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that the VenoValve® will be featured during a presentation at the Annual Charing Cross Symposium being held April 23-25, 2025 in London, England. As part of the Symposium, Dr. David Dexter, Sentara Hospital, Norfolk, Virginia and Associate Professor of Surgery, Eastern Virginia...

Read more

Alligator Bioscience Announces Initiation of HLX22 Phase 2 Trial in Breast Cancer by Shanghai Henlius Biotech, Inc.

April 23, 2025 6:00 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that Shanghai Henlius Biotech, Inc. ("Henlius") has initiated a Phase 2 clinical trial with HLX22, an anti-HER2 monoclonal antibody originally developed by Alligator's subsidiary, Atlas Therapeutics. HLX22 is being developed by Henlius under a sublicense from AbClon, Inc., which had previously licensed the antibody from Alligator. The Phase 2 study is being conducted in mainland China...

Read more

AbTherx and Rondo Therapeutics Announce Multi-Program Antibody Discovery Collaboration

April 23, 2025 6:00 AM

AbTherx, Inc., a biotechnology company with innovative transgenic technologies that enable and accelerate antibody discovery, today announced a technology license agreement with Rondo Therapeutics. The partnership will leverage AbTherx's innovative Atlas Binary Fixed Light Chain Transgenic Mouse technology to deliver antibodies against targets selected by Rondo. AbTherx's antibody discovery platform is powered by Atlas Mice, a suite of...

Read more

Vicore Announces Presentations at the 2025 American Thoracic Society International Conference

April 23, 2025 2:10 AM

Vicore Pharma Holding (STO:VICO) Stockholm, April 23, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the Company will present multiple oral presentations and posters at the 2025 American Thoracic Society (ATS) International Conference, taking place in San Francisco, California from May 16 - May 21, 2025. These posters and...

Read more

BioLumic Oversubscribed Funding Round Accelerates a New Category of Non-GMO Seed Traits

April 22, 2025 2:15 PM

BioLumic Inc., a pioneer in seed trait innovation, today announced the close of its oversubscribed Series B Extension, securing $8.3 million USD from new and existing investors, including Ki Tua Fund, Azolla Ventures, and iSelect Fund. The new capital will accelerate the commercial growth of a breakthrough category of seed traits - xTraits™ - the world's first seed traits activated purely by precise light signals. The round attracted a strategic...

Read more

CaaMTech Spins Out Transneural Therapeutics to Develop Novel Neuroplastogens

April 22, 2025 1:15 PM

CaaMTech, Inc. has spun out Transneural Therapeutics, Inc. (Transneural) to transform the treatment of neuropsychiatric and neurodegenerative diseases with novel neuroplastogens. Transneural emerges from stealth with a robust preclinical pipeline of non-hallucinogenic neuroplastogens designed to be best-in-class treatments for neuropsychiatric and neurodegenerative diseases. At the helm of Transneural is its CEO, Charmaine Lykins, a...

Read more

PulpFixin Unveils First-Ever, Moisture-Resistant, Fully Compostable Cryogenic Storage Boxes for Labs

April 22, 2025 1:00 PM

PulpFixin, a leader in sustainable labware innovation, today announced the release of its newest breakthrough: Cryogenic Boxes designed to replace polypropylene and polycarbonate plastic storage boxes in laboratories and biobanking environments. Most cryoboxes are either made of plastic or they are coated with polypropylene or polyethylene, rendering them unrecyclable. Plastic coated cardboard boxes cannot be composted, recycled, and should not...

Read more

Neurovation Labs Expands IP Portfolio With Patent for Precision Brain Biomarker Detection Technology

April 22, 2025 9:00 AM

Neurovation Labs, Inc., a precision neuroscience biotechnology company targeting physiological biomarkers of Post-traumatic Stress Disorder (PTSD) for comprehensive diagnosis and treatment, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 12,274,761, on April 15, 2025. The patent, entitled "Compositions and Methods to Detect GluA1 in Brain and to Identify the Presence of GluA1-Mediated PTSD," is directed to a...

Read more

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

April 21, 2025 9:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the addition of Frank Zaccanelli, Robert K. Coughlin, and Joseph Mangan to its Board of Advisors. The Advisory Board will provide strategic guidance as IGC advances its Alzheimer's drug development and AI driven early dementia detection programs. Frank Zaccanelli, a seasoned entrepreneur and former President, General Manager, and minority owner of the Dallas...

Read more

Moolec Science Enters Into Transformational Transaction Expanding Across Multiple Technology Platforms

April 21, 2025 7:00 AM

Moolec Science SA (NASDAQ:MLEC) ("The Company" or "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that it has entered into a Business Combination Agreement (the "BCA") with Bioceres Group Limited ("Bioceres Group") and other related entities in an all-stock transaction (the "Business Combination"). Subject to the terms and conditions of the BCA, which was...

Read more

Moolec Science Enters Into Transformational Transaction Expanding Across Multiple Technology Platforms

April 21, 2025 7:00 AM

Moolec Science SA (NASDAQ:MLEC) ("The Company" or "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that it has entered into a Business Combination Agreement (the "BCA") with Bioceres Group Limited ("Bioceres Group") and other related entities in an all-stock transaction (the "Business Combination"). Subject to the terms and conditions of the BCA, which was...

Read more

Paradromics Announces Stephen Ryu, MD, as Chief Medical Officer

April 17, 2025 1:00 PM

Paradromics Inc., a neurotechnology company developing the highest data-rate brain-computer interface (BCI) platform, today announced the appointment of Dr. Stephen Ryu as Chief Medical Officer (CMO). Dr. Ryu, a board certified neurosurgeon, is the Chair of Neurosurgery at the Palo Alto Medical Foundation and holds adjunct professorships in Electrical Engineering and Neurosurgery at Stanford University. Dr. Ryu has been a key figure in the...

Read more

Holding in Company

April 17, 2025 8:45 AM

Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON)(HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces that, on 16 April 2025, A&B (HK) Company Ltd (" A&B ") divested its entire shareholding of 3,559,893 ordinary shares representing approximately 3.40% of the Company's issued share capital. A&B (HK) Company Ltd, an investment and development company based in Hong Kong,...

Read more

Bora Biologics Unveils Cutting-Edge Innovations at Festival of Biologics 2025

April 17, 2025 7:00 AM

Bora Biologics is set to showcase its innovative Allosteric Formulation Platform at the Festival of Biologics 2025, demonstrating advancements in biologics development. This year's conference is taking place at the San Diego Convention Center, April 23-24, 2025. Attendees are invited to visit Booth 632 to discover how Bora Biologics' pioneering approaches can enhance biologics development. Pawel Stanczak, PhD, Director of Process and Drug...

Read more

Aspira Women’s Health Inc. to Begin Trading April 17th On OTC Under the Symbol "AWHL"

April 17, 2025 6:00 AM

Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that at beginning of trading on April 17, 2025, the Company expects that its Common Stock will begin trading under its new symbol "AWHL" on markets operated by the OTC Markets Group, Inc. This symbol replaces the prior symbol "AWH" under which the...

Read more